Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

14 Sep 2007 08:55

Phytopharm PLC14 September 2007 NOTIFICATION OF TRANSACTIONS OF DIRECTORS, PERSONS DISCHARGING MANAGERIALRESPONSIBILITY OR CONNECTED PERSONS This form is intended for use by an issuer to make a RIS notification requiredby DR 3.1.4R(1. (1) An issuer making a notification in respect of a transaction relating toshares or debentures of the issuer should complete boxes 1 to 16, 23 and 24. (2) An issuer making a notification in respect of a derivative relating tothe shares of the issuer should complete boxes 1 to 4, 6, 8, 13, 14, 16, 23 and24. (3) An issuer making a notification in respect of options granted to adirector/person discharging managerial responsibilities should complete boxes 1to 3 and 17 to 24. (4) An issuer making a notification in respect of a financial instrumentrelating to the shares of the issuer (other than a debenture) should completeboxes 1 to 4, 6, 8, 9, 11, 13, 14, 16, 23 and 24. Please complete all relevant boxes in block capital letters. 1. Name of the issuer 2. State whether the notification relates to (i) a transaction notified in accordance with DR 3.1.4R(1)(a); or PHYTOPHARM PLC (ii) DR 3.1.4R(1)(b) a disclosure made in accordance with section 324 (as extended by section 328) of the Companies Act 1985; or (iii) both (i) and (ii) NOTIFICATION RELATES TO (iii) 3. Name of person discharging 4. State whether notification managerial responsibilities/ relates to a person connected director with a person discharging managerial responsibilities/ director named in 3 and identify the connected person MR PIERS MORGAN AS 3 ABOVE 5. Indicate whether the notification 6. Description of shares (including is in respect of a holding of the class), debentures or derivatives person referred to in 3 or 4 or in or financial instruments relating respect of a non-beneficial to shares interest AS 3 ABOVE OPTIONS OVER ORDINARY SHARES OF 1 PENCE EACH 7. Name of registered shareholder(s) 8. State the nature of the and, if more than one, the number transaction of shares held by each of them GRANT OF AN SAYE SHARE OPTION UNDER THE PHYTOPHARM SHARESAVE PLAN 2007 9. Number of shares, debentures or 10. Percentage of issued class financial instruments relating to acquired (treasury shares of that shares acquired class should not be taken into account when calculating percentage) 11. Number of shares, debentures or 12. Percentage of issued class financial instruments relating to disposed (treasury shares of that shares disposed class should not be taken into account when calculating percentage) 13. Price per share or value of 14. Date and place of transaction transaction 15. Total holding following 16. Date issuer informed of notification and total percentage transaction holding following notification (treasury shares of that class should not be taken into account when calculating percentage) If a person discharging managerial responsibilities has been granted options bythe issuer complete the following boxes 17. Date of grant 18. Period during which or date on which it can be exercised 12 SEPTEMBER 2007 1 OCTOBER 2010 TO 31 MARCH 2011 19. Total amount paid (if any) for grant 20. Description of shares or of the option debentures involved (class and number) NIL 19,585 PHYTOHARM PLC ORDINARY 1 PENCE SHARES 21. Exercise price (if fixed at the time 22. Total number of shares or of grant) or indication that price is debentures over which options to be fixed at the time of exercise held following notification EXERCISE PRICE FORTY EIGHT AND ONE 334,585 QUARTER PENCE PER SHARE 23. Any additional information 24. Name of contact and telephone number for queries ZOE MCGOWAN 01480 437697 Name and signature of duly authorised officer of issuer responsible for makingnotification------------------------------------------------___ZOE MCGOWAN_________________________________________________________ Date of notification _14 SEPTEMBER 2007____________________________________ ------------------------------------------------ This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
16th Dec 20247:00 amRNS-RCommercial agreement with PETNET Solutions Inc
10th Dec 20247:00 amRNSContract Win
4th Dec 202411:35 amRNSShare Option Award & PDMR Dealings
4th Dec 20247:00 amRNSFinancial Results for year ended 30 September 2024
25th Nov 20247:00 amRNSNotice of Results and Investor Presentation
31st Oct 20247:00 amRNSShare Option Awards & PDMR Dealing
30th Oct 20244:50 pmRNSHolding(s) in Company
29th Oct 20244:00 pmRNSHolding(s) in Company
29th Oct 202410:58 amRNSHolding(s) in Company
28th Oct 20244:59 pmRNSHolding(s) in Company
28th Oct 202411:00 amRNSDirector/PDMR Shareholdings
25th Oct 202412:55 pmRNSResult of GM, Issue of Equity & TVR
22nd Oct 20243:00 pmRNSCorrection of clerical error
17th Oct 20247:00 amRNSHolding(s) in Company
16th Oct 20247:00 amRNSDirector/PDMR Shareholding
15th Oct 20247:00 amRNSResult of Retail Offer
10th Oct 20241:30 pmRNSExercise of Options & Director/PDMR Purchase
9th Oct 20247:00 amRNSResult of Placing and Subscription
8th Oct 20244:40 pmRNSRetail Offer
8th Oct 20244:35 pmRNSPlacing and Subscription
14th Aug 20247:01 amRNSTrading Update
14th Aug 20247:00 amRNSContract Win
5th Aug 20247:00 amRNSBoard Appointment
29th Jul 20247:00 amRNSFurther progress in HD consortium
20th Jun 20245:45 pmRNSHolding(s) in Company
19th Jun 20247:00 amRNSContract Win
23rd May 20247:00 amRNSContract Win
21st May 20247:00 amRNSHalf-year Report
7th May 20247:00 amRNSNotice of half year results
15th Apr 20247:00 amRNSLife Molecular Imaging – Neuraceq Supply Agreement
3rd Apr 20247:00 amRNSImeka Collaboration Agreement
13th Mar 20247:00 amRNSTrading Update
29th Jan 202412:00 pmRNSHolding(s) in Company
25th Jan 20244:00 pmRNSResult of AGM
12th Jan 20249:35 amRNSDirectorate Change
27th Dec 20237:00 amRNSUpdate regarding Nominated Adviser and Broker
15th Dec 20237:00 amRNSChange of Auditor
5th Dec 20237:00 amRNSFinancial Results for year ended 30 September 2023
27th Nov 20237:00 amRNSNotice of Results and Investor Presentation
5th Oct 20237:00 amRNSAppointment of Independent Non-Executive Director
29th Sep 20237:00 amRNSTrading Update
18th Jul 20237:00 amRNSContract Win
14th Jun 20237:00 amRNSContract Win
23rd May 20237:00 amRNSHalf year report
16th May 20237:00 amRNSInvestor Meet Company presentation
10th May 20237:00 amRNSTrading Update
3rd Apr 20238:35 amRNSExtension of Huntington's disease consortium
21st Mar 202312:11 pmRNSHolding(s) in Company
10th Mar 20237:00 amRNSContract Win
7th Feb 20237:00 amRNSTrading Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.